Alnylam yanks Amvuttra TV ad following FDA letter

Core Insights - Alnylam Pharmaceuticals has withdrawn a television advertisement for its drug Amvuttra after the U.S. FDA deemed the advertisement misleading [2] - Amvuttra is approved for treating two specific heart conditions: hereditary transthyretin-mediated amyloidosis (ATTR-CM) and polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) [3] Company Summary - The company faced regulatory scrutiny from the U.S. FDA regarding its advertising practices [2] - Amvuttra is positioned in the market for treating serious health conditions related to amyloidosis [3]